Stifel lowered the firm’s price target on RxSight (RXST) to $9 from $17 and keeps a Hold rating on the shares. The firm’s Light Adjustable Lens consignment inventory analysis shows normal customer inventory levels at the end of 1Q25, despite unexpected March LAL softness, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Closing Bell Movers: AES Corp jumps 14% on takeover possibility
- RxSight cuts FY25 revenue view to $120M-$130M from $160M-$175M